Certara (CERT) Competitors

$17.00
-0.06 (-0.35%)
(As of 05/10/2024 ET)

CERT vs. DH, TNDM, ACAD, MRUS, ACLX, ENOV, MLTX, OLK, QDEL, and BHC

Should you be buying Certara stock or one of its competitors? The main competitors of Certara include Definitive Healthcare (DH), Tandem Diabetes Care (TNDM), ACADIA Pharmaceuticals (ACAD), Merus (MRUS), Arcellx (ACLX), Enovis (ENOV), MoonLake Immunotherapeutics (MLTX), Olink Holding AB (publ) (OLK), QuidelOrtho (QDEL), and Bausch Health Companies (BHC). These companies are all part of the "medical" sector.

Certara vs.

Definitive Healthcare (NASDAQ:DH) and Certara (NASDAQ:CERT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, community ranking, risk, profitability, valuation and earnings.

In the previous week, Definitive Healthcare had 17 more articles in the media than Certara. MarketBeat recorded 35 mentions for Definitive Healthcare and 18 mentions for Certara. Definitive Healthcare's average media sentiment score of 0.57 beat Certara's score of -0.04 indicating that Certara is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Definitive Healthcare
0 Very Positive mention(s)
7 Positive mention(s)
9 Neutral mention(s)
7 Negative mention(s)
0 Very Negative mention(s)
Neutral
Certara
2 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Definitive Healthcare has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Certara has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500.

Certara has higher revenue and earnings than Definitive Healthcare. Certara is trading at a lower price-to-earnings ratio than Definitive Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Definitive Healthcare$251.41M2.50-$202.39M-$1.75-3.04
Certara$354.34M7.72-$55.36M-$0.39-43.59

Certara has a net margin of -17.02% compared to Certara's net margin of -78.16%. Definitive Healthcare's return on equity of 4.08% beat Certara's return on equity.

Company Net Margins Return on Equity Return on Assets
Definitive Healthcare-78.16% 0.51% 0.34%
Certara -17.02%4.08%2.79%

98.7% of Definitive Healthcare shares are held by institutional investors. Comparatively, 74.0% of Certara shares are held by institutional investors. 14.8% of Definitive Healthcare shares are held by insiders. Comparatively, 2.4% of Certara shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Certara received 1 more outperform votes than Definitive Healthcare when rated by MarketBeat users. Likewise, 34.92% of users gave Certara an outperform vote while only 30.00% of users gave Definitive Healthcare an outperform vote.

CompanyUnderperformOutperform
Definitive HealthcareOutperform Votes
21
30.00%
Underperform Votes
49
70.00%
CertaraOutperform Votes
22
34.92%
Underperform Votes
41
65.08%

Definitive Healthcare presently has a consensus target price of $9.94, indicating a potential upside of 86.93%. Certara has a consensus target price of $20.06, indicating a potential upside of 18.01%. Given Certara's higher possible upside, research analysts plainly believe Definitive Healthcare is more favorable than Certara.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Definitive Healthcare
0 Sell rating(s)
9 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.10
Certara
0 Sell rating(s)
7 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.36

Summary

Certara beats Definitive Healthcare on 13 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CERT vs. The Competition

MetricCertaraPrepackaged software IndustryMedical SectorNASDAQ Exchange
Market Cap$2.73B$21.48B$5.12B$7.81B
Dividend YieldN/A2.08%38.15%3.92%
P/E Ratio-43.5959.11111.8716.04
Price / Sales7.729.622,416.2074.58
Price / Cash17.9764.5048.8335.50
Price / Book2.599.535.334.38
Net Income-$55.36M$368.27M$106.58M$217.46M
7 Day Performance-3.41%-0.55%-0.89%-0.14%
1 Month Performance-3.79%-1.06%-1.39%0.05%
1 Year Performance-16.34%17.92%4.69%9.69%

Certara Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DH
Definitive Healthcare
3.9173 of 5 stars
$7.25
-1.2%
$11.31
+56.0%
-45.5%$853.98M$251.41M-4.07950Analyst Forecast
News Coverage
TNDM
Tandem Diabetes Care
3.4994 of 5 stars
$44.00
+1.1%
$43.80
-0.5%
+37.5%$2.81B$770.01M-20.282,400Positive News
ACAD
ACADIA Pharmaceuticals
4.033 of 5 stars
$17.25
+1.5%
$31.75
+84.1%
-28.5%$2.85B$726.44M-45.39597Earnings Report
Analyst Forecast
Short Interest ↑
Analyst Revision
News Coverage
MRUS
Merus
2.1043 of 5 stars
$48.73
+2.9%
$56.33
+15.6%
+113.4%$2.86B$43.95M-16.03172Earnings Report
Analyst Forecast
Analyst Revision
News Coverage
ACLX
Arcellx
3.1505 of 5 stars
$52.42
-0.5%
$75.64
+44.3%
+11.6%$2.79B$110.32M-35.66130Earnings Report
Analyst Forecast
News Coverage
ENOV
Enovis
2.9426 of 5 stars
$52.24
+2.6%
$75.43
+44.4%
-8.5%$2.87B$1.71B-34.836,550Short Interest ↑
MLTX
MoonLake Immunotherapeutics
2.6031 of 5 stars
$43.66
-1.9%
$74.46
+70.5%
+53.3%$2.79BN/A-57.4550Earnings Report
Analyst Forecast
Analyst Revision
News Coverage
OLK
Olink Holding AB (publ)
1.0237 of 5 stars
$23.22
+0.3%
$26.00
+12.0%
+8.0%$2.89B$169.60M-92.88707News Coverage
Positive News
QDEL
QuidelOrtho
4.8801 of 5 stars
$43.88
+1.1%
$61.60
+40.4%
-50.6%$2.93B$3.00B-274.257,100Analyst Forecast
BHC
Bausch Health Companies
3.7286 of 5 stars
$7.42
-1.3%
$11.33
+52.8%
+18.2%$2.72B$8.76B-5.9820,270Analyst Downgrade

Related Companies and Tools

This page (NASDAQ:CERT) was last updated on 5/12/2024 by MarketBeat.com Staff

From Our Partners